Clinical Observation of Xiakucao Oral Liquid in Treating Graves Disease

Phase 1

Recruiting

• Conditions: Graves Disease

• Registration Number: ITMCTR2100004714
• Lead Sponsor: Guang'anmen Hospital, China Academy of Chinese Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Aged between 18 and 65 years;
2. According to the diagnostic criteria of Graves disease who diagnosed with Graves disease and with goiter;
3. Who have signed informed consent.

Exclusion Criteria

1. Patients with thyrotoxicosis caused by causes other than Graves' disease, such as nodular toxic goiter and autonomous high-functioning thyroid adenoma;
2. Patients with active thyroid eye disease;
3. Patients with thyroid cancer and other malignant tumors;
4. Patients with abnormal liver and kidney function (ALT or AST > 2 times the upper limit of normal, Scr > upper limit of normal) and other serious diseases of the system;
5. Patients with a history of radioactive 131I or surgical treatment;
6. Women with pregnancy or lactation;
7. Have used antithyroid drugs or other drugs that may affect this test in the past two weeks;
8. Patients with hyperthyroidism crisis or hyperthyroidism with myasthenia gravis;
9. Those who are known to be allergic to the test drug or its components;
10. Researchers consider that they are not suitable for selection.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
PA;TSH;FT3;FT4;Alb;

Secondary Outcome Measures

Name	Time	Method
TGAb;TRAb;Goiter scale;TPOAb;